【摘要】 目的观察倍他乐克与安体舒通联合用于治疗肥厚型心肌病心力衰竭患者的临床疗效。方法选取肥厚型心肌病并发心力衰竭患者88例,按照随机数字表法,分为对照组和观察组,每组44例。对照组采用倍他乐克治疗,观察组采用倍他乐克与安体舒通联合治疗,比较两组临床疗效、治疗前后心功能变化和不良反应情况。结果两组治疗总有效率和血清钾离子(K+)水平比较,差异无统计学意义(P> 0.05);观察组治疗后的左心室射血分数(LVEF)高于对照组,心率(HR)低于对照组,差异有统计学意义(P <0.05);两组均未出现明显不良反应,发生率差异无统计学意义(P> 0.05)。结论倍他乐克与安体舒通联合用于肥厚型心肌病心力衰竭治疗的效果确切,可使患者心功能得到更为明显改善,优于单纯应用倍他乐克。更多还原

【Abstract】 Objective To study the clinical effects of betaloc combined with spironolactone in the treatment of patients with hypertrophic cardiomyopathy with heart failure. Methods Eighty-eight patients with hypertrophic cardiomyopathy complicated with heart failure were enrolled. According to the random number table method,they were divided into control group and observation group,with 44 cases in each group. The control group was treated with betaloc. The observation group was treated with betaloc and spironolactone. The clinical efficacy,cardiac function changes and adverse reactions before and after treatment were compared. Results There was no significant difference in the total effective rate and serum potassium ion(K+)between the two groups(P>0.05). The left ventricular ejection fraction(LVEF)of the observation group was higher than that of the control group and heart rate(HR). The difference was statistically significant(P<0.05). There was no significant adverse reaction in the two groups,and the difference was not statistically significant(P>0.05). Conclusion The combination of betaloc and spironolactone for the treatment of heart failure in hypertrophic cardiomyopathy is effective,which can improve the heart function of patients,which is better than the simple application of betaloc.更多还原